| Date | Time | Source | Headline | Symbol | Company |
| 06/07/2024 | 2:15PM | iHub Newswire | FeaturedDaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio | | |
| 06/05/2024 | 6:30AM | Business Wire | Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | NASDAQ:SAGE | Sage Therapeutics Inc |
| 05/07/2024 | 6:30AM | Business Wire | Sage Therapeutics to Participate in Upcoming May Investor Conferences | NASDAQ:SAGE | Sage Therapeutics Inc |
| 04/25/2024 | 6:30AM | Business Wire | Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress | NASDAQ:SAGE | Sage Therapeutics Inc |
| 04/17/2024 | 6:30AM | Business Wire | Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease | NASDAQ:SAGE | Sage Therapeutics Inc |
| 04/11/2024 | 6:30AM | Business Wire | Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/28/2024 | 6:30AM | Business Wire | Sage Therapeutics to Present at Upcoming March Investor Conferences | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/21/2024 | 4:35PM | Edgar (US Regulatory) | Form SC TO-I/A - Tender offer statement by Issuer: [Amend] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/15/2024 | 5:02PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/15/2024 | 5:02PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/14/2024 | 4:09PM | Edgar (US Regulatory) | Form SC TO-I/A - Tender offer statement by Issuer: [Amend] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/14/2024 | 7:49AM | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/14/2024 | 7:20AM | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/14/2024 | 6:45AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SAGE | Sage Therapeutics Inc |
| 02/14/2024 | 6:30AM | Business Wire | Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/31/2024 | 5:25PM | Edgar (US Regulatory) | Form SC TO-I/A - Tender offer statement by Issuer: [Amend] | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/31/2024 | 4:50PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/31/2024 | 6:30AM | Business Wire | Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/24/2024 | 4:10PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/23/2024 | 8:13AM | Edgar (US Regulatory) | Form SC TO-I - Tender offer statement by Issuer | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/08/2024 | 6:45AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/08/2024 | 6:32AM | Business Wire | Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/08/2024 | 6:30AM | Business Wire | Sage Therapeutics Announces Changes to Board of Directors | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/04/2024 | 4:07PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SAGE | Sage Therapeutics Inc |
| 01/02/2024 | 6:30AM | Business Wire | Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 | NASDAQ:SAGE | Sage Therapeutics Inc |
| 12/19/2023 | 8:32AM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:SAGE | Sage Therapeutics Inc |
| 12/19/2023 | 8:30AM | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:SAGE | Sage Therapeutics Inc |
| 12/14/2023 | 6:30AM | Business Wire | ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. | NASDAQ:SAGE | Sage Therapeutics Inc |
| 12/14/2023 | 6:30AM | GlobeNewswire Inc. | ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. | NASDAQ:SAGE | Sage Therapeutics Inc |
| 12/08/2023 | 9:00AM | Edgar (US Regulatory) | Form SC TO-C - Written communication relating to an issuer or third party | NASDAQ:SAGE | Sage Therapeutics Inc |